PHP
TEVA icon

Parkman Healthcare Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Parkman Healthcare Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-196,805
Closed -$4.34M – 104
2024
Q4 		$4.34M Sell
196,805
-88,489
-31% -$1.61M 0.58% 48
2024
Q3 		$5.14M Sell
285,294
-68,648
-19% -$1.2M 0.66% 53
2024
Q2 		$5.75M Sell
353,942
-99,648
-22% -$1.53M 0.77% 45
2024
Q1 		$6.4M Buy
+453,590
New +$5.72M 0.79% 45

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Parkman Healthcare Partners's TEVA Position: Q1 2025 in Review

Parkman Healthcare Partners sold out of Teva Pharmaceuticals (TEVA) in Q1 2025, closing a stake of 196,805 shares — an estimated $4.34M sold.

Parkman Healthcare Partners first reported a position in TEVA in Q1 2024 and held it in 4 quarters. The position peaked at $6.4M in Q1 2024. 561 funds tracked by Wall St. Rank hold TEVA as of Q1 2025.

  • Parkman Healthcare Partners reported no remaining Teva Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Parkman Healthcare Partners sold 196,805 Teva Pharmaceuticals shares in Q1 2025, an estimated $4.34M.
  • Parkman Healthcare Partners first reported a position in Teva Pharmaceuticals in Q1 2024 and held it in 4 quarters.
  • Parkman Healthcare Partners's Teva Pharmaceuticals position peaked at $6.4M in Q1 2024.
  • 561 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2025.

Based on Parkman Healthcare Partners's 13F filing for Q1 2025, filed 15 May 2025.